Belen Garijo, the CEO of Merck KGaA, says focus on growth and innovation is key to the German group’s future.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Global Anatomic Pathology Market size is expected to reach US$ 53.27 billion by 2031 from US$ 30.22 billion in 2023 to record ...

Scaffold Technology MarketThe global scaffold technology market is estimated to be valued at USD 1,490.7 million in 2024, marking the beginning of a transformative era fueled by consumer-centric ...

Merck reported positive results for its experimental treatment designed to protect infants from RSV. The mid to late-stage ...

It hasn't been the best quarter for Merck & Co., Inc. ( NYSE:MRK ) shareholders, since the share price has fallen ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Merck's (MRK) monoclonal antibody clesrovimab shows cuts RSV infections by 60% in infants, with a strong safety profile. Read ...

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

Merck Foundation in partnership with African First Ladies and Ministries of Health and Medical Societies provided out of total 2080 Scholarships, 830 Scholarships of one-year Post-Graduate Diploma and ...

Highlights:,Merck & Co Inc's experimental treatment, clesrovimab, has demonstrated positive results in a mid- to late-stage ...